Patient-based drug discovery's latest news
02.04.2024: World Autism Awareness Day
Link to photo source (UN) At Ksilink, it is one of our core missions to develop new therapeutic modalities to treat autism and particularly a rare form called Phelan McDermid...
New Study on the Impact of Endocrine Disrupting Chemicals on Parkinson’s Disease
New Study on the Impact of Endocrine Disrupting Chemicals on Parkinson’s Disease Ksilink, in collaboration with researchers from the University of Chieti in Italy, has published...
Review Article in JAMA Psychiatry
Schumann G, Andreassen OA, Banaschewski T, et al. Addressing Global Environmental Challenges to Mental Health Using Population Neuroscience: A Review. JAMA Psychiatry....
Press Release of the IMPACT consortium, engaged in finding novel therapies to fight Arrhythmogenic Cardiomyopathy
Thanks to the funding obtained from Horizon Europe, this research project aims to open up new therapeutic perspectives based on the results obtained from various disease models....
Meet us at ECNP Barcelona!
Ksilink will be part of the 36th ECNP Congress in Barcelona, from October 7th to 10th 2023. Meet Karen Schmitt at the poster P.0070 during the poster session on 08/10/23, 12:35 -...
Call for participants in the environMENTAL Project Consensus Conference
We are recruiting participants for a consensus conference about research on the link between the environment and #mentalhealth as part of the environMENTAL EU Project. Are you...
The “Young Investigators” prize was awarded to Ksilink’s PhD student!
Our PhD student Vivien Batoumeni had the pleasure and honor to be awarded with the "Young Investigators" prize at Printemps de la cardiologie congress organized by Réseau Avenir...
Ksilink takes part in the EIC pathfinder consortium IMPACT
We are very proud to contribute with our expertise in phenotypic and functional profiling of cardiac muscle disorders as a partner of another European consortium of excellence....
New publication: The JUMP Cell Painting dataset, studying the morphological impact of 136,000 chemical and genetic perturbations goes public
Since 2019, Ksilink has been part of the JUMP-Cell Painting Consortium, a collaboration between 10 pharmaceutical companies, six supporting technology companies, and two...
